MGI(SH:688114) Century Securities·2026-03-02 08:24Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests closely monitoring specific companies and technologies within the sector [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.32% from February 9 to February 27, underperforming compared to the Wind All A index (3.89%) and the CSI 300 index (1.44%) [3][8]. - Key segments such as medical consumables (3.64%), other biological products (2.78%), and raw materials (0.68%) showed positive performance, while offline pharmacies (-2.12%), chemical preparations (-1.53%), and pharmaceutical distribution (-1.37%) faced declines [3][11]. - BGI Genomics is strategically transitioning towards a "short-read long + long-read long + spatial omics" platform by divesting old capacities and acquiring new technologies, aiming to secure a competitive edge in the global life sciences upstream platform [3][12]. - The report emphasizes the importance of monitoring the clinical registration progress of nanopore sequencers and the capabilities of domestic medical equipment manufacturers in the global industrial ecosystem [3][12]. Market Weekly Review - From February 9 to February 27, the pharmaceutical and biotechnology sector declined by 0.32%, lagging behind the Wind All A index (3.89%) and the CSI 300 index (1.44%) [8]. - Medical consumables led the gains with a 3.64% increase, while offline pharmacies saw the largest decline at -2.12% [11]. Industry News and Key Company Announcements - WuXi XDC announced a strategic partnership with Earendil Labs to accelerate the development of next-generation ADC drugs, integrating advanced AI-driven antibody discovery capabilities [13]. - Pfizer China and Xianweida Biotech entered a commercialization agreement for a new GLP-1 receptor agonist, with potential payments reaching up to $495 million [13]. - BGI Genomics announced a strategic transaction with Swiss Rockets, selling its U.S. subsidiary CGI for $50 million while retaining key patents [3][12].